Christine Stuhlmiller joined SK Life Science in 2024 as Executive Director for Program Management. Christine brings a deep knowledge of project execution that spans the breadth of drug development, from Discovery through Commercialization, and she plays a key role in ensuring communication, risk identification, and alignment for development projects.

In her role as Executive Director of the Global Project Management team, Christine ensures end-to-end project leadership and coordination across SKLSI’s R&D initiatives. Her team manages timelines, resource planning, budgets, risk mitigation, and cross-functional communication to ensure successful execution of clinical programs.

Before joining the company, Christine led Program Management at SK Life Science Labs (formerly Proteovant) for 3 years, working with core leadership to establish corporate strategy and processes while also supporting internal Discovery projects and external collaborations. Previously, Christine spent 13 years with Bristol-Myers Squibb where she was Project Leader in Late Development, managing several global, cross-functional teams, including ONUREG® in acute myeloid leukemia through its initial FDA approval, and Director of Project Management in Early Development, focused on progressing Phase 1/2 assets in hematology and oncology. Prior to program management, Christine held finance-related positions in both public and private companies.

Christine earned her bachelor’s degree in Business Management and Marketing from Cornell University and her MBA in Finance and Marketing from Weatherhead School of Management at Case Western University.